{"id":15876,"date":"2021-12-14T13:01:04","date_gmt":"2021-12-14T13:01:04","guid":{"rendered":"https:\/\/incilab.az\/d%c9%99rman-s%c9%99viyy%c9%99l%c9%99ri-testl%c9%99r-qrupu\/"},"modified":"2023-09-14T09:05:16","modified_gmt":"2023-09-14T09:05:16","slug":"drug-levels-tests-group","status":"publish","type":"page","link":"https:\/\/incilab.az\/en\/drug-levels-tests-group\/","title":{"rendered":"Drug levels tests group"},"content":{"rendered":"

[vc_row][vc_column]

\r\n \r\n <\/div>\r\n
<\/div>
\r\n

ASA (SAL\u0130S\u0130LAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Asetilsalisil tur\u015fusu; ASA; Salisil tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Analgetik konsentrasiya<\/td>\n30-100 \u03bcg\/mL<\/td>\n<\/tr>\n
\u0130ltihab \u0259leyhin\u0259 konsentrasiya<\/td>\n\u00a0150-300 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>300 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ASETAM\u0130NOFEN<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Parasetamol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-30 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsantrasiya<\/td>\n>200 \u03bcg\/mL (d\u0259rman q\u0259bulundan\u00a04 saat sonra)<\/td>\n<\/tr>\n
>100 \u03bcg\/mL (d\u0259rman q\u0259bulundan\u00a08 saat sonra)<\/td>\n<\/tr>\n
>50 \u03bcg\/mL\u00a0(d\u0259rman q\u0259bulundan\u00a012 saat sonra)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ASET\u0130LSAL\u0130S\u0130L TUR\u015eUSU (SAL\u0130S\u0130LAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Asetilsalisil tur\u015fusu; ASA; Salisil tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Analgetik konsentrasiya<\/td>\n30-100 \u03bcg\/mL<\/td>\n<\/tr>\n
\u0130ltihab \u0259leyhin\u0259 konsentrasiya<\/td>\n\u00a0150-300 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>300 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u0130AZEPAM<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u00ad\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.1-1.0\u00a0 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>5.0 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u0130FEN\u0130LH\u0130DANTO\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Epdantoin; Fenitoin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-20 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>20 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

D\u0130QOKS\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>Q\u0259bul edilmi\u015f \u0259n son dozadan 8-12 saat sonra n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r. X\u0259st\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0KIMS (Kinetik inte\u00adraction of microparticles in solution)<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.8-2.0 ng\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>2.5 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

EPDANTO\u0130N (D\u0130FEN\u0130LH\u0130DANTO\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Epdantoin; Fenitoin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-20 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>20 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

ETOSUKS\u0130M\u0130D<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Petimit<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015fl\u0259m\u0259 zaman\u0131:\u00a0<\/strong>C\u00fcm\u0259<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>H\u0259min g\u00fcn saat 18.00<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259\u00adnin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtikkonsentrasiya<\/td>\n40-100\u03bcg\/mL<\/td>\n<\/tr>\n
Toksikkonsentrasiya<\/td>\n>150\u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FEN\u0130T\u0130ON (D\u0130FEN\u0130LH\u0130DANTO\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Epdantoin; Fenitoin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-20 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>20 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FENOBARB\u0130TAL<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Luminal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0X\u0259s\u00adt\u0259\u00adnin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-40 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n> 40 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur (Bax C\u0259d\u00adv\u0259l-20). Fenobarbitalla birlikd\u0259 va\u00adl\u00adproy tur\u015fusu v\u0259 salisilatlar istif\u0259d\u0259 olun\u00adduqda fenobarbital\u0131n s\u0259viyy\u0259si 40% art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

FK506 (TACROL\u0130MUS)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0FK506<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adpa\u00adrat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n5-20 ng\/mL<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n>40 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

GABAPENT\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Neurontin<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin son d\u0259rman istifad\u0259 vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir.<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n2-12 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>25 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KARBAMAZEP\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tegretol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>300\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adpa\u00adrat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsantrasiya<\/td>\n4-10 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsantrasiya<\/td>\n:> 15 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

KLONAZEPAM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Rivotril<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin son q\u0259bul etdiyi d\u0259rman pre\u00adpa\u00adrat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n27-75 ng\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>80 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAM\u0130CTAL (LAMOTR\u0130G\u0130NE)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lamictal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman preparat\u0131n\u0131n istifad\u0259 vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.5-4.0 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n> 8.0 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LAMOTR\u0130G\u0130NE<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Lamictal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman preparat\u0131n\u0131n istifad\u0259 vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.5-4.0 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n> 8.0 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130 (L\u0130T\u0130UM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Li<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcnum\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman preparat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildi\u00adrilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 son dozadan \u0259n az\u0131 12 saat sonra al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.5-1.0 mEq\/L<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n>2.0 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

L\u0130T\u0130UM<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Li<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>500 \u03bcL<\/p>\n

N\u00fcnum\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman preparat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildi\u00adrilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 son dozadan \u0259n az\u0131 12 saat sonra al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0AAS<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n0.5-1.0 mEq\/L<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n>2.0 mEq\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

LUM\u0130NAL (FENOBARB\u0130TAL)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Luminal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0X\u0259s\u00adt\u0259\u00adnin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-40 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n> 40 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur (Bax C\u0259d\u00adv\u0259l-20). Fenobarbitalla birlikd\u0259 va\u00adl\u00adproy tur\u015fusu v\u0259 salisilatlar istif\u0259d\u0259 olun\u00adduqda fenobarbital\u0131n s\u0259viyy\u0259si 40% art\u0131r<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

METOTREKSAT<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adparat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildi\u00adril\u00adm\u0259lidir. N\u00fcmun\u0259 al\u0131nd\u0131qdan sonra \u0259n q\u0131sa m\u00fcdd\u0259td\u0259 plazmas\u0131 ayr\u0131laraq, soyuq \u015f\u0259raitd\u0259 v\u0259 qaranl\u0131qda labo\u00adratoriyaya g\u00f6nd\u0259rilm\u0259lidir. Z\u0259if do\u00adzal\u0131 d\u0259rman preparat\u0131 istifad\u0259sind\u0259n (IV v\u0259 ya PO) 0.5 v\u0259 2 saat, y\u00fcks\u0259k dozal\u0131 infuziyalarda is\u0259 24, 48 v\u0259 72 saat sonra n\u00fcmun\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>FPIA<\/p>\n

Referens:<\/strong>4-6 saata 50 mg\/m2<\/sup>\u00a0-15 mg\/m2<\/sup>\u00a0doza IV infuziya \u015f\u0259klind\u0259 t\u0259tbiq olunduqda;<\/p>\n\n\n\n\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n24. Satda 5.0-10.0 \u03bcmol\/L<\/td>\n<\/tr>\n
Saatda 0.5-1.0 \u03bcmol\/L<\/td>\n<\/tr>\n
Saatda <0.2 \u03bcmol\/L<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n24 Saatda >10.0 \u03bcmol\/L<\/td>\n<\/tr>\n
48 Saatda >1.0 \u03bcmol\/L<\/td>\n<\/tr>\n
72 Saatda >0.2 \u03bcmol\/L<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

OXCARBAZEP\u0130NE<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>Trileptal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adparat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>Terapevtik konsantrasiya: 15-35 \u03bcg\/ mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PARASETAMOL (ASETAM\u0130NOFEN)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Parasetamol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:\u00a0<\/strong>200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-30 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsantrasiya<\/td>\n>200 \u03bcg\/mL (d\u0259rman q\u0259bulundan\u00a04 saat sonra)<\/td>\n<\/tr>\n
>100 \u03bcg\/mL (d\u0259rman q\u0259bulundan\u00a08 saat sonra)<\/td>\n<\/tr>\n
>50 \u03bcg\/mL\u00a0(d\u0259rman q\u0259bulundan\u00a012 saat sonra)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PET\u0130M\u0130T (ETOSUKS\u0130M\u0130D)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:\u00a0<\/strong>Petimit<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015fl\u0259m\u0259 zaman\u0131:\u00a0<\/strong>C\u00fcm\u0259<\/p>\n

N\u0259tic\u0259 verm\u0259 zaman\u0131:\u00a0<\/strong>H\u0259min g\u00fcn saat 18.00<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259\u00adnin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtikkonsentrasiya<\/td>\n40-100\u03bcg\/mL<\/td>\n<\/tr>\n
Toksikkonsentrasiya<\/td>\n>150\u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

PR\u0130M\u0130DON<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Mysoline<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259st\u0259nin q\u0259bul etdiyi d\u0259rman prepa\u00adrat\u0131n\u0131n son istifad\u0259 zaman\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n5-12 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksiki konsentrasiya:<\/td>\n>15 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

R\u0130VOTR\u0130L (KLONAZEPAM)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Rivotril<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin son q\u0259bul etdiyi d\u0259rman pre\u00adpa\u00adrat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>HPLC<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n27-75 ng\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>80 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin t\u0259yinind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SABR\u0130L (V\u0130GABATR\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sabril<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259 al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259st\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>Terapevtik konsentrasiya: 2-40 \u03bcg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SAL\u0130S\u0130L TUR\u015eUSU (SAL\u0130S\u0130LAT)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Asetilsalisil tur\u015fusu; ASA; Salisil tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Analgetik konsentrasiya<\/td>\n30-100 \u03bcg\/mL<\/td>\n<\/tr>\n
\u0130ltihab \u0259leyhin\u0259 konsentrasiya<\/td>\n\u00a0150-300 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>300 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

SAL\u0130S\u0130LAT<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Asetilsalisil tur\u015fusu; ASA; Salisil tur\u015fusu<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0Fermentativ<\/p>\n

Referens<\/strong>:<\/strong><\/p>\n\n\n\n\n\n
Analgetik konsentrasiya<\/td>\n30-100 \u03bcg\/mL<\/td>\n<\/tr>\n
\u0130ltihab \u0259leyhin\u0259 konsentrasiya<\/td>\n\u00a0150-300 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>300 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u00ad\u015fa\u00adhid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130KLOSPOR\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sandomim<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a01 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259\u00ads\u0259nin \u0259n son istifad\u0259 etdiyi d\u0259rman preparat\u0131n\u0131n zaman\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0C-0 s\u0259\u00adviy\u00ady\u0259si t\u0259yin edil\u0259c\u0259kdirs\u0259 n\u00fcmun\u0259 son dozadan 12 saat sonra al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong>\u00a0C-0 s\u0259viyy\u0259si \u00fc\u00e7\u00fcn tera\u00adpevtik konsentrasiya 150-500 ng\/mL-dir. C-2 s\u0259viyy\u0259si \u00fc\u00e7\u00fcn is\u0259 x\u0259st\u0259 v\u0259 transplantasiyadan as\u0131l\u0131 olaraq referens aral\u0131\u011f\u0131 m\u00fcxt\u0259liflik \u00a0g\u00f6st\u0259rir<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

S\u0130ROL\u0130MUS<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Rapamune<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>\u00a04-12 ng\/mL
\nBu g\u00f6st\u0259rici b\u00f6yr\u0259k transplanta\u00adsi\u00adyas\u0131ndan sonra, sirolimusun siklo\u00adsporin il\u0259 kombinasiya olunmu\u015f m\u00fcalic\u0259si t\u0259yin olunan x\u0259st\u0259l\u0259r \u00fc\u00e7\u00fcn q\u00fcvv\u0259d\u0259dir. Dig\u0259r orqan transplan\u00adtasiyalar\u0131 v\u0259 d\u0259rman kombi\u00adnasiyalar\u0131ndan as\u0131l\u0131 olaraq referens d\u0259yi\u015f\u0259 bil\u0259r. M\u00fcayin\u0259nin HPLC\/UV metodu il\u0259 icra olundu\u011fu m\u00fc\u015fahid\u0259 alt\u0131nda olan x\u0259st\u0259l\u0259rd\u0259 n\u0259z\u0259r\u0259 al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TACROLIMUS<\/a><\/h2>\r\n
\r\n
\r\n

inonim:<\/strong>\u00a0FK506<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>EDTA-l\u0131 tam qan<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0B\u0259n\u00f6v\u015f\u0259yi qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adpa\u00adrat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259\u00adlidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>MEIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n5-20 ng\/mL<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n>40 ng\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TEGRETOL (KARBAMAZEP\u0130N)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Tegretol<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131\u00adnaq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>300\u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:\u00a0<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adpa\u00adrat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

N\u00fcmun\u0259d\u0259n imtina s\u0259b\u0259bl\u0259ri:<\/strong>\u00a0Hemoliz<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsantrasiya<\/td>\n4-10 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsantrasiya<\/td>\n:> 15 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TEOF\u0130L\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0200 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

X\u0259st\u0259nin haz\u0131rlanmas\u0131:<\/strong>\u00a0N\u00fcmun\u0259 oral istifad\u0259d\u0259n 2 saat, venadaxili istifad\u0259d\u0259n is\u0259 30 d\u0259qiq\u0259 sonra al\u0131nmal\u0131d\u0131r<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n10-20 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksik konsentrasiya<\/td>\n>20 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:\u00a0<\/strong>D\u0259rman s\u0259viyy\u0259sinin t\u0259\u00adyi\u00adnind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TOP\u0130RAMAT<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Topomax<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a02 mL<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0FPIA<\/p>\n

Referens:<\/strong>\u00a05-20 \u03bcg\/mL (\u00c7oxsayl\u0131 d\u0259r\u00adman istifad\u0259sind\u0259 topiramat s\u0259\u00adviy\u00ady\u0259si \u00fc\u00e7\u00fcn h\u0259d\u0259f d\u0259y\u0259r 5-20 \u03bcg\/mL g\u00f6st\u0259rilir. D\u0259rm\u0259n s\u0259viyy\u0259si qiym\u0259tl\u0259n\u00addiril\u0259rk\u0259n yana\u015f\u0131 istifad\u0259 olu\u00adnan dig\u0259r d\u0259rmanlar, ya\u015f v\u0259 b\u00f6y\u00adr\u0259k funksiyalar\u0131 da n\u0259z\u0259r\u0259 al\u0131n\u00admal\u0131d\u0131r)<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

TR\u0130LEPTAL (OXCARBAZEP\u0130NE)<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>Trileptal<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>\u00a0Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>500 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin q\u0259bul etdiyi son d\u0259rman pre\u00adparat\u0131n\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildiril\u00adm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>Terapevtik konsantrasiya: 15-35 \u03bcg\/ mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

VALPROY TUR\u015eUSU<\/a><\/h2>\r\n
\r\n
\r\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0300 \u03bcL<\/p>\n

N\u00fcmun\u0259nin al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259s\u00adt\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:\u00a0<\/strong>FPIA<\/p>\n

Referens:<\/strong><\/p>\n\n\n\n\n
Terapevtik konsentrasiya<\/td>\n50-100 \u03bcg\/mL<\/td>\n<\/tr>\n
Toksiki konsentrasiya<\/td>\n>100 \u03bcg\/mL<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin mu\u015fahid\u0259sind\u0259\u00a0 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section>

\r\n

V\u0130GABATR\u0130N<\/a><\/h2>\r\n
\r\n
\r\n

Sinonim:<\/strong>\u00a0Sabril<\/p>\n

N\u00fcmun\u0259 n\u00f6v\u00fc:\u00a0<\/strong>Serum<\/p>\n

N\u00fcmun\u0259 qab\u0131:<\/strong>\u00a0Q\u0131rm\u0131z\u0131 qapaql\u0131 s\u0131naq \u015f\u00fc\u015f\u0259si<\/p>\n

N\u00fcmun\u0259 miqdar\u0131:<\/strong>\u00a0500 \u03bcL<\/p>\n

N\u00fcmun\u0259 al\u0131nma qaydas\u0131:<\/strong>\u00a0X\u0259st\u0259nin \u0259n son q\u0259bul etdiyi d\u0259rman\u0131n vaxt\u0131 v\u0259 dozas\u0131 bildirilm\u0259lidir<\/p>\n

\u0130\u015f prinsipi:<\/strong>\u00a0HPLC<\/p>\n

Referens:<\/strong>\u00a0Terapevtik konsentrasiya: 2-40 \u03bcg\/mL<\/p>\n

\u0130stifad\u0259si:<\/strong>\u00a0D\u0259rman s\u0259viyy\u0259sinin m\u00fc\u015fahid\u0259sind\u0259 istifad\u0259 olunur<\/p>\n\r\n <\/div>\r\n <\/div>\r\n <\/section><\/div>[\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"

[vc_row][vc_column][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-15876","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/comments?post=15876"}],"version-history":[{"count":2,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15876\/revisions"}],"predecessor-version":[{"id":15915,"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/pages\/15876\/revisions\/15915"}],"wp:attachment":[{"href":"https:\/\/incilab.az\/en\/wp-json\/wp\/v2\/media?parent=15876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}